Halozyme Therapeutics, Inc. (0J2O.L)
USD 48.78
(0.12%)
USD 48.78
(0.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.38 Billion USD | 8.57% |
| 2022 | 1.27 Billion USD | 67.81% |
| 2021 | 757.95 Million USD | 203.76% |
| 2020 | 249.52 Million USD | -11.64% |
| 2019 | 282.4 Million USD | 312.61% |
| 2018 | 68.44 Million USD | 103.64% |
| 2017 | 33.61 Million USD | -77.57% |
| 2016 | 149.85 Million USD | 2191.04% |
| 2015 | 6.54 Million USD | 156.74% |
| 2014 | -11.52 Million USD | -151.43% |
| 2013 | 22.41 Million USD | 132.58% |
| 2012 | -68.78 Million USD | -30.22% |
| 2011 | -52.82 Million USD | 36.55% |
| 2010 | -83.25 Million USD | -23.41% |
| 2009 | -67.46 Million USD | -5.88% |
| 2008 | -63.71 Million USD | 34.77% |
| 2007 | -97.67 Million USD | -121.05% |
| 2006 | -44.18 Million USD | -130.97% |
| 2005 | -19.13 Million USD | -19.52% |
| 2004 | -16 Million USD | -33588.39% |
| 2003 | -47.51 Thousand USD | -115.7% |
| 2002 | 302.75 Thousand USD | 1258.77% |
| 2001 | -26.12 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.36 Billion USD | -0.93% |
| 2024 Q2 | 1.34 Billion USD | -1.66% |
| 2024 Q3 | 1.34 Billion USD | 0.34% |
| 2023 Q4 | 1.38 Billion USD | 12.87% |
| 2023 Q2 | 1.27 Billion USD | -8.81% |
| 2023 Q1 | 1.39 Billion USD | 9.91% |
| 2023 Q3 | 1.22 Billion USD | -4.03% |
| 2023 FY | 1.38 Billion USD | 8.57% |
| 2022 FY | 1.27 Billion USD | 67.81% |
| 2022 Q4 | 1.27 Billion USD | -6.29% |
| 2022 Q1 | 759.81 Million USD | 0.24% |
| 2022 Q2 | 1.15 Billion USD | 52.04% |
| 2022 Q3 | 1.35 Billion USD | 17.49% |
| 2021 Q2 | 427.77 Million USD | 14.28% |
| 2021 Q1 | 374.32 Million USD | 50.01% |
| 2021 Q4 | 757.95 Million USD | 97.37% |
| 2021 Q3 | 384.02 Million USD | -10.23% |
| 2021 FY | 757.95 Million USD | 203.76% |
| 2020 Q1 | 284.61 Million USD | 0.78% |
| 2020 Q3 | 327.89 Million USD | 27.85% |
| 2020 Q4 | 249.52 Million USD | -23.9% |
| 2020 FY | 249.52 Million USD | -11.64% |
| 2020 Q2 | 256.47 Million USD | -9.89% |
| 2019 Q4 | 282.4 Million USD | 5982.45% |
| 2019 FY | 282.4 Million USD | 312.61% |
| 2019 Q3 | 4.64 Million USD | -74.09% |
| 2019 Q2 | 17.92 Million USD | -60.01% |
| 2019 Q1 | 44.81 Million USD | -34.53% |
| 2018 FY | 68.44 Million USD | 103.64% |
| 2018 Q4 | 68.44 Million USD | -25.15% |
| 2018 Q3 | 91.44 Million USD | -17.52% |
| 2018 Q2 | 110.87 Million USD | 27.23% |
| 2018 Q1 | 87.14 Million USD | 159.27% |
| 2017 Q2 | 96.28 Million USD | -42.97% |
| 2017 FY | 33.61 Million USD | -77.57% |
| 2017 Q1 | 168.84 Million USD | 12.67% |
| 2017 Q4 | 33.61 Million USD | -20.83% |
| 2017 Q3 | 42.45 Million USD | -55.91% |
| 2016 Q4 | 149.85 Million USD | -0.75% |
| 2016 FY | 149.85 Million USD | 2191.04% |
| 2016 Q2 | 146.9 Million USD | 15.74% |
| 2016 Q1 | 126.92 Million USD | 1840.44% |
| 2016 Q3 | 150.99 Million USD | 2.78% |
| 2015 FY | 6.54 Million USD | 156.74% |
| 2015 Q3 | -21.72 Million USD | -20.57% |
| 2015 Q1 | 5.42 Million USD | 147.08% |
| 2015 Q2 | -18.01 Million USD | -431.89% |
| 2015 Q4 | 6.54 Million USD | 130.11% |
| 2014 FY | -11.52 Million USD | -151.43% |
| 2014 Q2 | -6.31 Million USD | 76.4% |
| 2014 Q3 | 3.46 Million USD | 154.79% |
| 2014 Q1 | -26.77 Million USD | -219.46% |
| 2014 Q4 | -11.52 Million USD | -433.02% |
| 2013 Q4 | 22.41 Million USD | 51.35% |
| 2013 Q2 | 3.89 Million USD | 149.36% |
| 2013 Q1 | -7.88 Million USD | 88.54% |
| 2013 FY | 22.41 Million USD | 132.58% |
| 2013 Q3 | 14.8 Million USD | 280.61% |
| 2012 FY | -68.78 Million USD | -30.22% |
| 2012 Q4 | -68.78 Million USD | 21.49% |
| 2012 Q3 | -87.61 Million USD | 14.14% |
| 2012 Q2 | -102.04 Million USD | 12.49% |
| 2012 Q1 | -116.6 Million USD | -120.74% |
| 2011 Q4 | -52.82 Million USD | 20.36% |
| 2011 FY | -52.82 Million USD | 36.55% |
| 2011 Q2 | -79.11 Million USD | -7.16% |
| 2011 Q1 | -73.82 Million USD | 11.32% |
| 2011 Q3 | -66.32 Million USD | 16.16% |
| 2010 Q1 | -55.17 Million USD | 18.21% |
| 2010 Q2 | -41.31 Million USD | 25.13% |
| 2010 Q3 | -89.84 Million USD | -117.47% |
| 2010 FY | -83.25 Million USD | -23.41% |
| 2010 Q4 | -83.25 Million USD | 7.33% |
| 2009 Q2 | -89.24 Million USD | -43.79% |
| 2009 Q3 | -77.63 Million USD | 13.0% |
| 2009 Q4 | -67.46 Million USD | 13.1% |
| 2009 FY | -67.46 Million USD | -5.88% |
| 2009 Q1 | -62.06 Million USD | 2.59% |
| 2008 Q3 | -72.49 Million USD | 12.03% |
| 2008 Q2 | -82.41 Million USD | 10.96% |
| 2008 Q1 | -92.55 Million USD | 5.24% |
| 2008 Q4 | -63.71 Million USD | 12.11% |
| 2008 FY | -63.71 Million USD | 34.77% |
| 2007 Q3 | -105.11 Million USD | -4.49% |
| 2007 Q2 | -100.59 Million USD | -41.74% |
| 2007 Q1 | -70.97 Million USD | -60.61% |
| 2007 FY | -97.67 Million USD | -121.05% |
| 2007 Q4 | -97.67 Million USD | 7.07% |
| 2006 Q4 | -44.18 Million USD | -174.45% |
| 2006 Q2 | -15.09 Million USD | 14.06% |
| 2006 Q3 | -16.1 Million USD | -6.63% |
| 2006 FY | -44.18 Million USD | -130.97% |
| 2006 Q1 | -17.57 Million USD | 8.16% |
| 2005 Q3 | -6.63 Million USD | 34.04% |
| 2005 Q1 | -13.13 Million USD | 17.98% |
| 2005 Q2 | -10.06 Million USD | 23.38% |
| 2005 Q4 | -19.13 Million USD | -188.33% |
| 2005 FY | -19.13 Million USD | -19.52% |
| 2004 Q2 | -5.93 Million USD | -104.62% |
| 2004 Q3 | -3.48 Million USD | 41.41% |
| 2004 FY | -16 Million USD | -33588.39% |
| 2004 Q4 | -16 Million USD | -359.95% |
| 2004 Q1 | 128.47 Million USD | 270481.52% |
| 2003 Q4 | -47.51 Thousand USD | 24.15% |
| 2003 Q3 | -62.64 Thousand USD | 9.55% |
| 2003 FY | -47.51 Thousand USD | -115.7% |
| 2003 Q1 | -73.11 Thousand USD | 24.82% |
| 2003 Q2 | -69.25 Thousand USD | 5.27% |
| 2002 Q3 | -111.79 Thousand USD | 8.58% |
| 2002 Q1 | -13.5 Thousand USD | 0.0% |
| 2002 Q2 | -122.28 Thousand USD | -805.67% |
| 2002 Q4 | -97.24 Thousand USD | 13.01% |
| 2002 FY | 302.75 Thousand USD | 1258.77% |
| 2001 FY | -26.12 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 1685.103% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1194.958% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 4218.704% |
| Perrigo Company plc | 3.32 Billion USD | 58.434% |
| Illumina, Inc. | 1.21 Billion USD | -13.746% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 94.855% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1312.488% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 83.232% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 89.258% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -851.831% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 5195.491% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -19113.552% |
| Waters Corporation | 1.96 Billion USD | 29.563% |
| Biogen Inc. | 6.28 Billion USD | 78.041% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 19548.986% |
| Evolus, Inc. | 63.7 Million USD | -2067.511% |
| Adicet Bio, Inc. | -142 Million USD | 1072.395% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 15415.861% |
| bluebird bio, Inc. | 108.57 Million USD | -1171.866% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -201.042% |
| FibroGen, Inc. | 56.76 Million USD | -2332.537% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -20.601% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -19717.206% |
| Homology Medicines, Inc. | 18.43 Million USD | -7389.711% |
| Geron Corporation | 14.76 Million USD | -9254.908% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 12.896% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -597.184% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1467.398% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 2645.116% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1339.545% |
| Zoetis Inc. | 4.76 Billion USD | 71.002% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 13811.429% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 34.18% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -264.59% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 114.438% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 9576.242% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -30.979% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -4230.808% |
| Verastem, Inc. | -37.27 Million USD | 3804.271% |
| Nektar Therapeutics | 210.24 Million USD | -556.81% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 791.057% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 3851.978% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -42.597% |
| OPKO Health, Inc. | 230.68 Million USD | -498.604% |
| Exelixis, Inc. | -73.05 Million USD | 1990.319% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -678.837% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 1119.851% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 1014.343% |
| uniQure N.V. | -102.95 Million USD | 1441.296% |
| Imunon, Inc. | -4.69 Million USD | 29484.928% |
| Blueprint Medicines Corporation | 702.83 Million USD | -96.472% |
| Insmed Incorporated | 721.62 Million USD | -91.358% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 4523.481% |
| TG Therapeutics, Inc. | 17.86 Million USD | -7630.814% |
| Incyte Corporation | -3.17 Billion USD | 143.491% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -80.318% |